Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors

Keyphrases

• Design Evaluation 100%
• Synthetic Evaluation 100%
• Biological Evaluation 100%
• Deguelin 100%
• Heat Shock Protein 90 Inhibitor 100%
• MCF-7 Cells 66%
• High Temperature 33%
• Further Development 33%
• Dose Effect 33%
• Sigma Phase 33%
• Western Blot Analysis 33%
• Apoptosis 33%
• Flow Cytometry 33%
• Cancer Cell Lines 33%
• MCF-7 Cancer Cell Line 33%
• Cell Cycle Arrest 33%
• Heat Shock Protein 90 (Hsp90) 33%
• Client Proteins 33%
• Synthesized Compounds 33%
• Structure-activity Relationship 33%
• Ubiquitin-proteasome System 33%
• C-ring 33%
• Biological Studies 33%
• G2 Phase 33%
• Antiproliferative Potency 33%
• Binding Potency 33%
• Addition Compounds 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Heat Shock Protein 90 Inhibitor 100%
• Deguelin 100%
• Structure Activity Relationship 33%
• Western Blot 33%
• Flow Cytometry 33%
• Malignant Neoplasm 33%
• Lead Compound 33%
• Breast Cancer 33%
• Heat Shock Protein 90 33%
• Ubiquitin 33%
• Proteasome 33%

Immunology and Microbiology

• Heat Shock 100%
• Western Blot 25%
• Cancer Cell Line 25%
• Cell Cycle G2 Phase 25%
• Cell Cycle Arrest 25%
• Structure Activity Relation 25%
• Proteasome 25%
• Cell Cycle Checkpoint 25%
• Programmed Cell Death 25%
• Ubiquitins 25%